Drug Discovery

The relentless pursuit of a cancer treatment that spares the patient while obliterating the tumor has led researchers to an architectural marvel smaller than a speck of dust. Modern oncology faces a persistent paradox where the very drugs designed to save lives often cause profound systemic damage

The biological fortress surrounding a solid tumor often acts as an impenetrable barrier, rendering many of the most advanced medical breakthroughs of the last decade ineffective against the vast majority of adult cancers. While the oncology field has celebrated monumental victories in treating

The long-standing struggle to bridge the gap between initial laboratory success and actual therapeutic effectiveness has led the pharmaceutical industry to fundamentally rethink how molecular interactions are measured. For many years, the standard approach involved testing potential drug compounds

The medical community is currently witnessing a profound shift in how we approach the most aggressive childhood cancers, moving away from the blunt force of radiation toward the elegant precision of molecular reprogramming. Rhabdomyosarcoma, or RMS, remains a high-stakes challenge in pediatric

The pharmaceutical landscape often operates on a razor's edge where multi-billion dollar investments can be validated or neutralized by a single data readout from a Phase 3 clinical trial. Merck and Gilead Sciences currently find themselves navigating this volatility as they balance the demands of

Ivan Kairatov is a seasoned veteran in biopharmaceutical research and development, having spent nearly two decades navigating the complex intersection of molecular biology and clinical strategy. With a deep specialization in small molecule innovation and a career dedicated to the evolution of